Press Release

Budget Conferees Should Pursue Regular Order for Reform

PhRMA May 1, 2013

Washington, D.C. (April 3, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin today released the following statement in support of regular order for health care reform:

“PhRMA maintains its strong support for health care reform and will do all that it can to help ensure that legislation gets on the President’s desk this year. We believe it is critical for this issue to remain on the front burner so that all Americans can access high-quality and affordable health care coverage.

“The health reform process so far has experienced a significant shift from what we’ve seen in years past – a healthy dose of bipartisanship that has allowed a diverse group of stakeholders to build consensus around ideas that can help strengthen the U.S. health care system while also addressing its weaknesses.

“To help keep the bipartisan spirit alive, PhRMA urges the budget conferees to pursue a process of regular order for health care reform so that members on both sides of the aisle can continue to have an open and constructive debate about important health care reform policy changes. In addition, we believe that pursuing health reform through reconciliation would preclude Congress from considering a number of critical reforms that fall outside the scope of a reconciliation bill.

“PhRMA will continue to work with members of Congress, the Administration and other stakeholders to build support around the need for comprehensive health care reform.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on the danger of imported drugs, visit: